Drugs / recombinant human interference'- α- 1b, interleukin-2, thalidomide, Venentoclax and Azacitidine
recombinant human interference'- α- 1b, interleukin-2, thalidomide, Venentoclax and Azacitidine
also known as
IFN-α- 1b
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| — | NCT06256627 Comparator | Jul 2023 → Mar 2025 overdue | acute myeloid leukemia | Henan Cancer Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant human interference'- α- 1b, interleukin-2, thalidomide, Venentoclax and Azacitidine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06256627 ↗ |
| Known as | IFN-α- 1b | “Analyzing the effect of "IFN-α- 1b, il-2, and thalidomide" on negative conversion rate of MRD .” NCT06256627 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human interference'- α- 1b” NCT06256627 ↗ |